A combination therapy with anti-IL5/5R and anti-IL4/IL13R has been administered in the aforementioned real-life studies [46,47,48,49] in patients on therapy with dupilumab and experiencing reactive hypereosinophilia to provide better control of both asthma and nasal polyposis while preventing other hypereosinophilia-related disorders. This evidence concerns the gene IL5 and asthma.